Saturday, April 04, 2020 11:56:51 PM
AIM - added at 1.77 (though my average is about 2.00 now). ER is on 3/31 so that's latest we'll hear something. Expecting an update on the Japan COVID trials and the P1 data for the cancer trials they were working on prior to all this.
Recent AIM News
- AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast • GlobeNewswire Inc. • 05/09/2024 12:50:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 12:30:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 12:30:31 PM
- AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® • GlobeNewswire Inc. • 05/06/2024 12:30:00 PM
- AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer • GlobeNewswire Inc. • 04/29/2024 12:55:00 PM
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 04/25/2024 12:45:00 PM
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 04/18/2024 12:45:00 PM
- AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs • GlobeNewswire Inc. • 04/15/2024 12:55:00 PM
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 04/11/2024 03:00:00 PM
- AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer • GlobeNewswire Inc. • 04/10/2024 12:21:00 PM
- AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 04/02/2024 11:30:00 AM
- AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference • GlobeNewswire Inc. • 03/28/2024 12:05:00 PM
- AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast • GlobeNewswire Inc. • 03/26/2024 01:05:00 PM
- AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research • GlobeNewswire Inc. • 03/25/2024 01:05:00 PM
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 03/22/2024 12:55:00 PM
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 03/20/2024 01:25:00 PM
- AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity • GlobeNewswire Inc. • 03/15/2024 12:45:00 PM
- AIM ImmunoTech Announces Launch of CEO Corner Platform • GlobeNewswire Inc. • 03/07/2024 01:45:00 PM
- AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 01:45:00 PM
- Form D/A - Notice of Exempt Offering of Securities: [Amend] • Edgar (US Regulatory) • 02/21/2024 03:37:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:31:03 PM
- AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer • GlobeNewswire Inc. • 02/14/2024 01:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 08:47:35 PM
- AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions • GlobeNewswire Inc. • 02/08/2024 01:50:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM